Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer

BMC Cell Biology

Volumn 7, Issue , 2006, Pages

  Tafuri, Luciene S A ^a   Rocha, Gislene F S ^a   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P53; PROTEIN P63;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; BREAST RECONSTRUCTION; BREAST REDUCTION; CANCER RISK; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MYOEPITHELIUM CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; FEMALE; HUMANS; HYPERPLASIA; KI-67 ANTIGEN; MEMBRANE PROTEINS; MENOPAUSE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748481786     PISSN: 14712121     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-7-29     Document Type: Article

References (43)

1. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-68.
2. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL: Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993, 68:540-8.
3. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. Embo J 1999, 18:1223-34.
4. Bankfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, Fuzesi L, Lelle RJ, Bocker W: Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract 2000, 196:489-501.
5. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, et at.: p21 WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996, 74:208-15.
6. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C: p63, a p53 homologue, is a selective nuclear marker of myoepithellial cells of the human breast. Am J Surg Pathol 2001, 25:1054-60.
7. Barboule N, Baldin V, S JO, Vidal S, Valette A. Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA. Int J Cancer 1998, 76:891-6.
8. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, et al.: Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996, 2:1591-9.
9. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-91.
10. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 1995, 92:5545-9.
11. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Feldstein-Teruya J, Pohar K, Hoos A, Cordon-Cardo C: p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002, 8:494-501.
12. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146-51.
13. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19:403-410. Histopathology 2002, 41:151.
14. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, et al.: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-78.
15. Gobbi H, Dupont WD, Parl FF, Schuyler PA, Plummer WD, Olson SJ, Page DL: Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units. Int J Cancer 2005, 113:857-9.
16. Gohring UJ, Bersch A, Becker M, Neuhaus W, Schondorf T: p21 (waf) correlates with DNA replication but not with prognosis in invasive breast cancer. J Clin Pathol 2001, 54:866-70.
17. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth factor beta I associates with disease progression in human breast cancer. Cancer Res 1992, 52:6949-52.
18. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, et al.: Benign breast disease and the risk of breast cancer. N Engl J Med 2005, 353:229-37.
19. Iqbal M, Davies MP, Shoker BS, Jarvis C, Sibson DR, Sloane JP. Sub-groups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells. J Pathol 2001, 193:333-8.
20. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998, 90:37-42.
21. Krishnamurthy S, Sneige N: Molecular and biologic markers of premalignant lesions of human breast. Adv Anat Pathol 2002, 9:185-97.
22. Lakhani SR, Collins N, Stratton MR, Sloane JP, Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995, 48:611-5.
23. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-80.
24. London SJ, ConnoIly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. Jama 1992, 267:941-4.
25. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA: Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997, 6:297-301.
26. Melo E, Alves V: Determinação da fraçãode proliferação celular no câncer de mama pela marcação imunoistoquímica do antígeno nuclear Ki-67: comparação quantitativa e semi-quantitativa. J Bras Patol 1999, 35:2000.
27. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP: Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum Pathol 1998, 29:1539-45.
28. Orend G, Chiquet-Ehrismann R: Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp Cell Res 2000, 261:104-10.
29. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003, 56:214-20.
30. Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta C, Bal de Kier Joffe E, Puricelli L: Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep 2004, 12:1143-50.
31. Reis-Filho JS, Schmitt FC: Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002, 9:280-9.
32. Rey MJ, Fernandez PL, Jares P, Munoz M, Nadal A, Peiro N, Nayach I, Mallofre C, Muntane J, Campo E, et al: p21 WAF1/Cip1 is associated with cyclin DICCNDI expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol 1998, 184:265-71.
33. Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandao DF, Chahud F, Zucoloto S: p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005, 47:458-66.
34. Schmitt FC: Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 1995, 31A:2049-52.
35. Schnitt SJ: Benign breast disease and breast cancer risk morphology and beyond. Am J Surg Pathol 2003, 27:836-41.
36. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP: Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999, 155:1811-5.
37. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol 2005, 205:248-54.
38. Tavassoli FA, Norris HJ: A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990, 65:518-29.
39. Tavassoli FA, Schnitt S, Hoefler H, Boecker W, Rosai J, Heywang-Köbrunner H, Monfair RF, Ellis IO, Lakhani SR: Intraductal proliferative lesions. In World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Breast Female Genital Organs Edited by: Tavassoli FA, Devilee P. Lion: IARC Press; 2003:63-75.
40. Thor AD, Liu S 2nd, Moore DH, Shi Q, Edgerton SM: p(21 WAF1 CIP1) expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat 2000, 61:33-43.
41. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K: p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002, 9:216-9.
42. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL: Cytoplasmic p21 WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003, 5:R242-9.
43. Yang A, Kaghad M, Caput D, McKeon F: On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002, 18:90-5.